Monograph Details
|
|
Ob/Gyn
> Menopause and HRT
|
|
ESTRACE |
| Manufacturer |
|
Warner Chilcott Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Estrogen. |
| Generic Name |
|
Estradiol 0.5mg, 1mg, 2mg+; scored tabs; +contains tartrazine. |
| Indications |
|
Moderate to severe vasomotor symptoms of menopause. Atrophic vaginitis. Hypoestrogenism. Osteoporosis prevention. |
| Children |
|
Not applicable. |
| Adults |
|
Menopause, hypoestrogenism: 1–2mg daily, given cyclically (3 weeks on, 1 week off). Osteoporosis prevention (begin therapy soon after menopause): 0.5mg daily for 3 weeks, then stop for 1 week, then recycle; adjust. Reevaluate periodically. |
| Contraindications |
|
Breast or estrogen-dependent cancer. Thrombophlebitis. Thromboembolic disorders. Undiagnosed abnormal genital bleeding. Pregnancy (Cat.X). |
| Precautions |
|
Patients with intact uterus should almost always receive a progestin to avoid endometrial hyperplasia. Asthma (2mg tabs). Hepatic dysfunction. Conditions aggravated by fluid retention. Familial hyperlipoproteinemia. Do initial complete physical examination and repeat annually (include BP, mammogram, and PAP smear). Discontinue if jaundice occurs. Nursing mothers. |
| Adverse Reactions |
|
See literature. Mastodynia, breast secretion, uterine bleeding, dysmenorrhea, amenorrhea, GI upset, headache, hypertension, edema, hypercalcemia, gallbladder or thromboembolic disease, skin changes. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
